首页> 美国卫生研究院文献>Neuro-Oncology >Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma
【2h】

Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma

机译:循环中的U2小核RNA片段作为原发性中枢神经系统淋巴瘤的新型诊断生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundPrimary central nervous system lymphomas (PCNSLs) are highly aggressive tumors. Chemotherapy has improved prognosis significantly; however, early diagnosis is crucial for effective treatment. Presently, the diagnosis of PCNSL depends on histopathology of tumor biopsies. We have previously demonstrated differential expression of microRNAs in cerebrospinal fluid (CSF) samples from patients with PCNSL. Based on promising findings about circulating U2 small nuclear RNA fragments (RNU2-1f) as novel blood-based biomarkers for pancreatic, colorectal, and lung cancer, we investigated RNU2-1f in the CSF of PCNSL patients.
机译:背景原发性中枢神经系统淋巴瘤(PCNSLs)是高度侵袭性肿瘤。化学疗法可显着改善预后;但是,早期诊断对于有效治疗至关重要。当前,PCNSL的诊断取决于肿瘤活检的组织病理学。我们先前已经证明了PCNSL患者脑脊液(CSF)样品中microRNA的差异表达。基于关于循环U2小核RNA片段(RNU2-1f)作为胰腺,结肠直肠癌和肺癌的新型基于血液的生物标记物的有希望的发现,我们研究了PCNSL患者CSF中的RNU2-1f。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号